Regeneron Q3 Revenue Jumps 36% to $5.1B; Non-GAAP EPS Up 70% to $20.07, Guidance Raised
REGN sits 45% above its 52-week low of $591.52.
Summary
Regeneron posted 36% revenue growth to $5.1 billion and 70% non-GAAP EPS growth to $20.07 in Q3 2026, with record Dupixent, EYLEA HD and Libtayo sales, and raised its full-year margin guidance.
Key Events · Earnings and Guidance · REGN
-
Q3 Revenue Up 36% to $5.1B
Total revenues rose to $5,116 million from $3,754 million a year ago, with Sanofi collaboration revenue up 68% to $2,724 million.
-
Non-GAAP EPS Jumps 70% to $20.07
GAAP diluted EPS was $18.45 (up 35%) and non-GAAP diluted EPS $20.07 (up 70%) versus $11.83 in Q3 2025.
-
Record Product Sales Across Portfolio
Dupixent global net sales rose 35% to $6.54 billion, EYLEA HD U.S. net sales 62% to $699 million, and Libtayo global 51% to $550 million.
-
2026 Guidance Raised on Margins
GAAP gross margin guidance lifted to approximately 80% and non-GAAP to approximately 86%; GAAP R&D raised to $6.600-$6.735 billion while SG&A guidance was lowered.
Analysis · REGN · Life Sciences
Regeneron delivered a blowout quarter, with revenue up 36% to $5.1 billion and non-GAAP EPS up 70% to $20.07. Record Dupixent, EYLEA HD and Libtayo sales drove the top line, and the first full quarter without the Sanofi Development Balance drag added further lift. Management raised full-year gross margin guidance to roughly 80% GAAP / 86% non-GAAP and lifted R&D spend while trimming SG&A, a mix that points to operating leverage on top of top-line growth. The $1.0 billion Sanofi up-front lands in Q4 collaboration revenue, with up to $7.0 billion more in milestones. Next scheduled item: an FDA decision on cemdisiran in generalized myasthenia gravis expected next month.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REGN was trading at $856.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $84.3B. The 52-week trading range was $591.52 to $859.34. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.